Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues
- 1 January 1994
- journal article
- research article
- Published by Oxford University Press (OUP) in Protein Engineering, Design and Selection
- Vol. 7 (6), 805-814
- https://doi.org/10.1093/protein/7.6.805